Cullinan Therapeutics receives price target increase to $42.00

Cullinan Therapeutics (NASDAQ: CGEM) has seen a boost in its price objective, with Wedbush raising its target from $39.00 to $42.00. The brokerage maintains an 'outperform' rating on the stock. Other analysts have provided mixed outlooks, including a 'buy' rating from BTIG Research and a 'sell' rating from Weiss Ratings.

The clinical-stage biopharmaceutical company has experienced significant share price momentum driven by positive clinical readouts. Its pipeline includes candidates such as Zipalertinib, CLN-049, CLN-978, and Velinotamig, which target autoimmune diseases and cancer.

Key developments include the rolling New Drug Application (NDA) submission to the FDA for Zipalertinib to treat specific non-small cell lung cancer (NSCLC) mutations. Additionally, the company has reported clinical data regarding CLN-049 for acute myeloid leukemia and CLN-978 for autoimmune conditions.